Marksans Pharma Limited has announced that UK MHRA has granted Market Authorisation to the Company s wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.
Marksans Pharma Ltd. today raised Rs.372.40 crores through the conversion of warrants into equity shares by OrbiMed Asia IV Mauritius FVCI Limited, and Mr. Mark Saldanha, Promoter of the Company.